Alnylam Pharmaceuticals and The Alpha-1 Project have entered into a collaboration agreement for the continued advancement of ALN-AAT.
ALN-AAT is a subcutaneously administrated RNAi therapeutic in development for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.
TAP’s mission is to work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the pursuit of cures and therapies for chronic obstructive pulmonary disease (COPD) and liver disease caused by AAT deficiency.
TAP is partially funding research activities for ALN-AAT.
Detailed financial terms of the research agreement were not disclosed.
Alnylam remains on track to file an investigational new drug application for this program in mid-2015.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity